178 related articles for article (PubMed ID: 35458427)
1. Drug Resistance Mechanism of M46I-Mutation-Induced Saquinavir Resistance in HIV-1 Protease Using Molecular Dynamics Simulation and Binding Energy Calculation.
Rana N; Singh AK; Shuaib M; Gupta S; Habiballah MM; Alkhanani MF; Haque S; Reshi MS; Kumar S
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458427
[TBL] [Abstract][Full Text] [Related]
2. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
3. Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency.
Goldfarb NE; Ohanessian M; Biswas S; McGee TD; Mahon BP; Ostrov DA; Garcia J; Tang Y; McKenna R; Roitberg A; Dunn BM
Biochemistry; 2015 Jan; 54(2):422-33. PubMed ID: 25513833
[TBL] [Abstract][Full Text] [Related]
4. Insights into the mechanism of drug resistance: X-ray structure analysis of G48V/C95F tethered HIV-1 protease dimer/saquinavir complex.
Prashar V; Bihani SC; Das A; Rao DR; Hosur MV
Biochem Biophys Res Commun; 2010 Jun; 396(4):1018-23. PubMed ID: 20471372
[TBL] [Abstract][Full Text] [Related]
5. Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors.
Bastys T; Gapsys V; Walter H; Heger E; Doncheva NT; Kaiser R; de Groot BL; Kalinina OV
Retrovirology; 2020 May; 17(1):13. PubMed ID: 32430025
[TBL] [Abstract][Full Text] [Related]
6. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
7. Structure, dynamics and solvation of HIV-1 protease/saquinavir complex in aqueous solution and their contributions to drug resistance: molecular dynamic simulations.
Wittayanarakul K; Aruksakunwong O; Sompornpisut P; Sanghiran-Lee V; Parasuk V; Pinitglang S; Hannongbua S
J Chem Inf Model; 2005; 45(2):300-8. PubMed ID: 15807491
[TBL] [Abstract][Full Text] [Related]
8. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.
Markland W; Rao BG; Parsons JD; Black J; Zuchowski L; Tisdale M; Tung R
J Virol; 2000 Aug; 74(16):7636-41. PubMed ID: 10906218
[TBL] [Abstract][Full Text] [Related]
9. Understanding Drug Resistance of Wild-Type and L38HL Insertion Mutant of HIV-1 C Protease to Saquinavir.
Venkatachalam S; Murlidharan N; Krishnan SR; Ramakrishnan C; Setshedi M; Pandian R; Barh D; Tiwari S; Azevedo V; Sayed Y; Gromiha MM
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833460
[TBL] [Abstract][Full Text] [Related]
10. Revealing the drug resistance mechanism of saquinavir due to G48V and V82F mutations in subtype CRF01_AE HIV-1 protease: molecular dynamics simulation and binding free energy calculations.
C S V; Munusami P
J Biomol Struct Dyn; 2023 Feb; 41(3):1000-1017. PubMed ID: 34919029
[TBL] [Abstract][Full Text] [Related]
11. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
[TBL] [Abstract][Full Text] [Related]
12. The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.
Canducci F; Ceresola ER; Saita D; Al-Abed Y; Garotta G; Clementi M; Nicoletti F
Antiviral Res; 2011 Sep; 91(3):292-5. PubMed ID: 21763726
[TBL] [Abstract][Full Text] [Related]
13. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
[TBL] [Abstract][Full Text] [Related]
14. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of binding of potential ADMET/tox screened saquinavir analogues for inhibition of HIV-protease via molecular dynamics and binding free energy calculations.
Jayaswal A; Pathak E; Mishra H; Shah K
J Biomol Struct Dyn; 2022 Sep; 40(14):6439-6449. PubMed ID: 33663345
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
Hong L; Zhang XC; Hartsuck JA; Tang J
Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
Prashar V; Bihani SC; Ferrer JL; Hosur MV
Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
[TBL] [Abstract][Full Text] [Related]
18. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
[TBL] [Abstract][Full Text] [Related]
19. Cantilever-centric mechanism of cooperative non-active site mutations in HIV protease: Implications for flap dynamics.
Sherry D; Worth R; Ismail ZS; Sayed Y
J Mol Graph Model; 2021 Jul; 106():107931. PubMed ID: 34030114
[TBL] [Abstract][Full Text] [Related]
20. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]